3 Healthcare Stocks That Are Screaming Deals Right Now

Amidst market uncertainty, the article highlights three undervalued healthcare stocks for contrarian investors: DaVita (DVA), Merck (MRK), and Universal Health Services (UHS). DaVita, trading at 11x forward P/E, offers upside despite recent challenges, driven by international expansion and share repurchase dynamics. Merck, at 9x forward P/E, could see a re-rating as its robust drug pipeline and new Keytruda formulations mitigate patent expiration concerns. Similarly, Universal Health Services, trading at a discount to peers at 9x forward P/E, is positioned for a re-rating and stock appreciation through sustained earnings growth.

Analysis

Amidst increasing market uncertainty, the healthcare sector is attracting attention as a defensive play, with specific opportunities for contrarian investors in undervalued stocks. DaVita (DVA) has experienced a 14% year-to-date decline due to factors like disappointing earnings and a ransomware attack, yet its 11x forward P/E valuation appears attractive. The perceived negative of Berkshire Hathaway trimming its stake is linked to a share repurchase agreement, not a lack of confidence, while international expansion and a stable U.S. core business could drive future earnings improvements.

Merck (MRK), trading at 9x forward earnings, faces a significant patent expiration for its blockbuster drug Keytruda in 2028. However, the potential launch of Keytruda Qlex and a robust pipeline of 20 potential blockbuster drugs, representing $50 billion in revenue, could mitigate this risk. Successful development and commercialization of these initiatives could lead to a moderate re-rating, aligning its valuation with other pharmaceutical peers.

Universal Health Services (UHS), a profitable acute care and behavioral healthcare provider, trades at a discount with a 9x forward P/E compared to peers like Tenet Healthcare (13x) and HCA Healthcare (15x). Sustained earnings growth, in line with sell-side analyst forecasts, is expected to not only support stock appreciation but also facilitate a moderate re-rating to narrow this valuation gap. These three companies present distinct catalysts for potential valuation expansion despite current headwinds.

Key Decisions for Investors

• Investors should closely monitor DaVita's international expansion and share repurchase activity as key drivers for potential valuation expansion, despite recent stock pressure.
• For Merck, evaluate the progress of its Keytruda Qlex launch and the development of its pipeline drugs as critical factors in mitigating the 2028 patent cliff and supporting a re-rating.
• Consider Universal Health Services as a potential value play, tracking its earnings growth against analyst forecasts for signs of sustained performance that could close its valuation discount relative to peers.